JP2011503207A - 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法 - Google Patents

循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法 Download PDF

Info

Publication number
JP2011503207A
JP2011503207A JP2010534249A JP2010534249A JP2011503207A JP 2011503207 A JP2011503207 A JP 2011503207A JP 2010534249 A JP2010534249 A JP 2010534249A JP 2010534249 A JP2010534249 A JP 2010534249A JP 2011503207 A JP2011503207 A JP 2011503207A
Authority
JP
Japan
Prior art keywords
pim
cell
heart
cells
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010534249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011503207A5 (https=
Inventor
ムラスキ，ジョン，エー．，ジュニア
サスマン，マーク，エー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
San Diego State University Research Foundation
Original Assignee
San Diego State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by San Diego State University Research Foundation filed Critical San Diego State University Research Foundation
Publication of JP2011503207A publication Critical patent/JP2011503207A/ja
Publication of JP2011503207A5 publication Critical patent/JP2011503207A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/12—Dual-specificity kinases (2.7.12)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
JP2010534249A 2007-11-16 2008-11-14 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法 Pending JP2011503207A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98875307P 2007-11-16 2007-11-16
US9169808P 2008-08-25 2008-08-25
PCT/US2008/083693 WO2009065080A1 (en) 2007-11-16 2008-11-14 Compositions and method for manipulating pim-1 activity in circulatory system cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014154915A Division JP5795670B2 (ja) 2007-11-16 2014-07-30 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2011503207A true JP2011503207A (ja) 2011-01-27
JP2011503207A5 JP2011503207A5 (https=) 2012-01-05

Family

ID=40639186

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010534249A Pending JP2011503207A (ja) 2007-11-16 2008-11-14 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法
JP2014154915A Expired - Fee Related JP5795670B2 (ja) 2007-11-16 2014-07-30 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014154915A Expired - Fee Related JP5795670B2 (ja) 2007-11-16 2014-07-30 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法

Country Status (5)

Country Link
US (5) US8617534B2 (https=)
EP (1) EP2209889B1 (https=)
JP (2) JP2011503207A (https=)
CA (1) CA2705862C (https=)
WO (1) WO2009065080A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2864100A1 (en) 2012-02-14 2013-08-22 The Regents Of The University Of California Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
EA201690458A1 (ru) 2013-08-23 2016-07-29 Инсайт Корпорейшн Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CA3067558A1 (en) 2017-06-16 2018-12-20 Avery Therapeutics, Inc. Three dimensional tissue compositions and methods of use
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CN108913655B (zh) * 2018-07-16 2022-07-15 浙江大学 基于多能干细胞技术建立“人源性”心肌肥大模型的方法
US20210386827A1 (en) * 2018-10-15 2021-12-16 Avery Therapeutics, Inc. Cell-free compositions and methods for restoration or enhancement of tissue function
EP4103214B1 (en) 2020-02-13 2026-04-29 Tenaya Therapeutics, Inc. Gene therapy vectors for treating heart disease
WO2022050045A1 (ja) * 2020-09-04 2022-03-10 デクセリアルズ株式会社 導電性積層体及びこれを用いた光学装置、導電性積層体の製造方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004521108A (ja) * 2001-01-18 2004-07-15 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ δＰＫＣの活性化および阻害のためのペプチド
WO2004113367A1 (ja) * 2003-06-24 2004-12-29 Keio University アポトーシス抑制活性を有するペプチド
JP2005501802A (ja) * 2001-01-23 2005-01-20 ボストン　サイエンティフィック　コーポレイション 虚血心筋を処置するための限局性心筋注入方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US20040132190A1 (en) 1995-02-28 2004-07-08 The Regents Of The University Of California Gene therapy for myocardial ischemia
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6007839A (en) 1996-02-16 1999-12-28 The Liposome Company, Inc. Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
US5869037A (en) * 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes
CN1234835A (zh) * 1996-09-05 1999-11-10 加利福尼亚大学董事会 充血性心力衰竭的基因治疗
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
US7198784B2 (en) 1996-10-17 2007-04-03 Oxford Biomedica (Uk) Limited Retroviral vectors
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
IL132463A0 (en) 1997-05-13 2001-03-19 Univ North Carolina Lentivirus - based gene transfer vectors
US6063400A (en) 1997-07-02 2000-05-16 Sdg, Inc. Targeted liposomal constructs for diagnostic and therapeutic uses
CA2304983A1 (en) 1997-09-24 1999-04-01 The Regents Of The University Of California Non-primate lentiviral vectors and packaging systems
ES2373406T3 (es) 1997-12-22 2012-02-03 Oxford Biomedica (Uk) Limited Vectores basados en el virus de la anemia infecciosa equina (vaie).
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6867348B1 (en) * 1999-12-16 2005-03-15 Xenogen Corporation Methods and compositions for screening for angiogenesis modulating compounds
US7122181B2 (en) 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
US20030003582A1 (en) 2001-05-08 2003-01-02 Tranzyme, Inc. Trans-viral vector mediated gene transfer to the retina
US7732199B2 (en) * 2001-07-12 2010-06-08 Geron Corporation Process for making transplantable cardiomyocytes from human embryonic stem cells
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
RU2305708C2 (ru) 2001-10-02 2007-09-10 Энститю Клейтон Де Ля Решерш Рекомбинантный лентивирусный вектор, клетка-хозяин, трансдуцированная лентивирусным вектором, способ ее трансдукции и применение
CA2505251A1 (en) * 2002-11-05 2004-05-27 Brigham And Women's Hospital, Inc. Mesenchymal stem cells and methods of use thereof
CN100567502C (zh) * 2003-04-03 2009-12-09 株式会社康福来 药学制剂
US7135339B2 (en) 2003-11-20 2006-11-14 University Of Iowa Research Foundation Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)
JP3903061B2 (ja) 2003-12-24 2007-04-11 株式会社Ｌｔｔバイオファーマ 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤
US20050266067A1 (en) 2004-03-02 2005-12-01 Shiladitya Sengupta Nanocell drug delivery system
WO2006014035A1 (en) 2004-08-06 2006-02-09 Biospectrum, Inc. Multiple layered liposome and preparation method thereof
CN101087563A (zh) * 2004-11-08 2007-12-12 约翰霍普金斯大学 活检钳
CA2609937A1 (en) * 2005-05-27 2006-11-30 The Hospital For Sick Children Modulation of the integrin linked kinase signaling pathway to promote cardiac cell proliferation and self-renewal
CN101267805A (zh) 2005-07-27 2008-09-17 普洛体维生物治疗公司 制造脂质体的系统和方法
WO2010135401A2 (en) 2009-05-19 2010-11-25 San Diego State University Foundation Kinase-mediated cytoprotection and enhanced cellular engraftment and persistence

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004521108A (ja) * 2001-01-18 2004-07-15 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ δＰＫＣの活性化および阻害のためのペプチド
JP2005501802A (ja) * 2001-01-23 2005-01-20 ボストン　サイエンティフィック　コーポレイション 虚血心筋を処置するための限局性心筋注入方法
WO2004113367A1 (ja) * 2003-06-24 2004-12-29 Keio University アポトーシス抑制活性を有するペプチド

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6013032817; Ａｋｓｏｙ　Ｉ　ｅｔ　ａｌ．: 'Ｓｅｌｆ-ｒｅｎｅｗａｌ　ｏｆ　ｍｕｒｉｎｅ　ｅｍｂｒｙｏｎｉｃ　ｓｔｅｍ　ｃｅｌｌｓ　ｉｓ　ｓｕｐｐｏｒｔｅｄ　ｂｙ　ｔｈｅ　ｓｅｒｉｎｅ／ｔｈｒｅｏｎｉｎｅ　ｋｉｎａｓｅｓ　Ｐｉｍ-１　ａｎｄ　Ｐ' Ｓｔｅｍ　Ｃｅｌｌｓ． Ｖｏｌ．２５　Ｎｏ．１２, 20070823, ｐｐ．２９９６-３００４ *
JPN7013002473; Ｍｕｒａｓｋｉ　ＪＡ　ｅｔ　ａｌ．: 'Ｐｉｍ-１　ｒｅｇｕｌａｔｅｓ　ｃａｒｄｉｏｍｙｏｃｙｔｅ　ｓｕｒｖｉｖａｌ　ｄｏｗｎｓｔｒｅａｍ　ｏｆ　Ａｋｔ' Ｃｉｒｃｕｌａｔｉｏｎ Ｖｏｌ．１１４　Ｎｏ．１８　Ｓｕｐｐｌ．Ｓ, 20061031, ｐｐ．２９４ *

Also Published As

Publication number Publication date
CA2705862A1 (en) 2009-05-22
JP5795670B2 (ja) 2015-10-14
JP2015007063A (ja) 2015-01-15
US20160324936A1 (en) 2016-11-10
US20100316701A1 (en) 2010-12-16
US20210322522A1 (en) 2021-10-21
EP2209889B1 (en) 2016-07-20
WO2009065080A1 (en) 2009-05-22
US20140234265A1 (en) 2014-08-21
US8617534B2 (en) 2013-12-31
EP2209889A4 (en) 2012-09-05
CA2705862C (en) 2018-03-27
EP2209889A1 (en) 2010-07-28
US20190060417A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
JP5795670B2 (ja) 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法
ES2770073T3 (es) Uso terapéutico de proteínas morfogenéticas óseas
JP2016516423A (ja) 心筋症を処置するための遺伝子治療ベクター
JP7193874B2 (ja) 筋肉Ａキナーゼアンカータンパク質（ｍＡＫＡＰ）作用の阻害による心臓病の処置
US9550981B2 (en) Modified tafazzin proteins and methods of making and using the same
CN1882687B (zh) 心肌细胞的增殖方法
CN112472690B (zh) 一种制备增强CNPase活性的化合物或生物药物的方法用于治疗心脏疾病
CN109937045A (zh) 局部缺血/再灌注损伤
ES3006614T3 (en) Relaxin receptor 1 for use in treatment and prevention of heart failure
KR102175170B1 (ko) HBV enhancer 억제인자 ACK1을 포함하는 B형 간염 치료용 조성물
US20070213263A1 (en) Methods And Compositions Using Adiponectin For Treatment Of Cardiac Disorders And For Stimulation Of Angiogenesis
US8496928B2 (en) Method for preventing and treating cardiovascular diseases with BRCA1
CN101125198A (zh) Hsp27在改善缺血后心脏收缩功能方面的应用
Pan et al. Myofibroblast-specific inhibition of ASPP1 alleviates myocardial fibrosis by enhancing p53 degradation
EP3689896A1 (en) Grk2 modulating mirnas
Maharsy Enhancing Cardiomyocyte Survival in Drug Induced Cardiac Injury
Tsui The Role of p21-Activated Kinase 1 (Pak1) in the Heart

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20101110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130926

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140401